Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRACTION-Gastric Cancer
NL-OMON55766Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab, ipilimumab, relatlimab and rucaparib in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (5 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Overall response rate at 24 weeks, Duration of response and 1 more. Started Oct 2017; status: completed.
02
Drugs
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NL-OMON55766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55766.